Richard Mularski to Antiviral Agents
This is a "connection" page, showing publications Richard Mularski has written about Antiviral Agents.
Connection Strength
0.566
-
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Ann Intern Med. 2022 12; 175(12):1716-1727.
Score: 0.202
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
Score: 0.187
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
Score: 0.177